

June 2017

MERGER & ACQUISITION

Strides Shasun announces joint venture with Vivimed labs.

Strides Shasun on Thursday informed that it has signed agreements with Vivimed labs to set up two joint venture companies. Both will be 50:50 joint venture companies. One of the companies in India will own the US FDA approved formulation facility in Alathur, Chennai, and the other company in Singapore will own certain approved ANDAs and product pipeline, as per BSE filing.

Read More: http://www.indiainfoline.com/article/news-top-story/strides-shasun-jv-strides-shasun-announces-joint-venture-with-vivimed-labs-117051900462_1.html



Pfizer Ltd enters into acquisition agreement with AstraZeneca.

Pharma major Pfizer Ltd has entered into acquisition agreement with AstraZeneca AB, Sweden pursuant to which the brand “Neksium” is being acquired by the company in India. The consideration amounted to Rs 75 crores, subject to completion of necessary conditions. Neksium complements the company’s existing product portfolio in the gastrointestinal (GI) therapeutic area.

Read More: http://www.indiainfoline.com/article/news-top-story/pfizer-pfizer-ltd-enters-into-acquisition-agreement-with-astrazeneca-117053101042_1.html

Sun Pharma buys Ocular, adding late-stage dry-eye candidate to take on Allergan blockbuster.

India’s Sun Pharma is stumping up \$40 million plus undisclosed milestones to buy Ocular Technologies from Auvon Therapeutics, adding to its growing eyecare medicines pipeline.

Read More: <http://www.fiercepharma.com/pharma-asia/sun-pharma-buys-ocular-adding-late-stage-dry-eye-candidate-to-take-allergan-blockbuster>

AstraZeneca's controversial castoffs continue with \$300M heart-drug sale to Recordati.

As promised, AstraZeneca is forging ahead with its castoff strategy—and this time, rights to an aged beta blocker are on their way out the door.

Read More: <http://www.fiercepharma.com/pharma/az-s-controversial-castoffs-continue-300m-heart-med-sale-to-recordati>

GlaxoSmithKline aims for the whole consumer-health shebang with \$10.3B Novartis JV buyout.

Next March, GlaxoSmithKline will have the option to buy out Novartis’ stake in the pair’s industry-leading consumer health JV. And it may already be getting prepared.

The British drugmaker is getting its ducks in a row for an £8 billion (\$10.3 billion) offer for its partner’s 36.5% share, top shareholders told The Sunday Times. Industry watchers say Novartis could use the extra dough to help fund a megatakeover—and word is, the potential target is AstraZeneca.

Read More: <http://www.fiercepharma.com/pharma/gsk-preps-10-3b-buyout-novartis-consumer-jv-stake>